Osmont Marie-Noëlle, Malrain Cécile, Ruellan Anne-Lise, Benchikh Amine, Herlem Emmanuelle, Polard Elisabeth, Scailteux Lucie-Marie
Pharmacovigilance, Pharmacoepidemiology and Drug Information Centre, Department of Clinical Pharmacology, Rennes University Hospital, Rennes, 35033, France.
Department of Neurology, Rennes University Hospital, Rennes, 35033, France.
BMC Neurol. 2024 Dec 31;24(1):494. doi: 10.1186/s12883-024-04004-4.
Reversible cerebral vasoconstriction syndrome (RCVS) is characterized by severe headaches, often thunderclap headaches, and a multifocal constriction of the cerebral arteries. Although RCVS can occur spontaneously, some cases occur after exposure to drugs. We describe the first case of RCVS in which methylphenidate, a drug with vasoconstrictive properties, is the only suspected drug. Still an unexpected adverse drug reaction of methylphenidate, and so far observed with the concomitant use of vasoactive drugs and methylphenidate, RCVS can be observed when methylphenidate is used alone.
A 44-year-old French female presented with sudden onset of severe thunderclap headache during exercise. She had been treated for about 2 years with 54 mg extended-release MPH twice a week for attention deficit / hyperactivity disorder. After clinical, biological and imaging examinations, clinicians concluded to a highly probable RCVS diagnosis, probably linked to methylphenidate use. Major causes of RCVS were ruled out and the methylphenidate treatment was discontinued. The outcome was favourable with nimodipine treatment. We also describe two other cases of methylphenidate induced RCVS recorded in French Pharmacovigilance Database. Moreover, RCVS is an adverse reaction reported more frequently than expected with methylphenidate in the International Pharmacovigilance Database (VigiBase®), suggesting a pharmacovigilance signal. Given its pharmacodynamics, i.e. pre-synaptic dopamine and norepinephrine reuptake inhibition, methylphenidate is theoretically likely to contribute to this vascular event.
The role of methylphenidate needs to be considered in case of RCVS diagnosis observed in a treated patient. Although the frequency of this potential adverse drug reaction is expected to be rare, clinicians should be aware of its possible occurrence, given the ever-increasing use of methylphenidate.
可逆性脑血管收缩综合征(RCVS)的特征是严重头痛,常为霹雳样头痛,以及脑动脉多灶性收缩。虽然RCVS可自发发生,但有些病例在接触药物后出现。我们描述了首例RCVS病例,其中唯一可疑药物是具有血管收缩特性的哌醋甲酯。RCVS仍是哌醋甲酯意外的药物不良反应,且迄今在血管活性药物与哌醋甲酯合用时观察到,单独使用哌醋甲酯时也可观察到。
一名44岁法国女性在运动期间突然出现严重霹雳样头痛。她因注意力缺陷/多动障碍接受约2年每周两次54毫克缓释哌醋甲酯治疗。经临床、生物学和影像学检查后,临床医生得出高度可能为RCVS诊断的结论,可能与使用哌醋甲酯有关。排除了RCVS的主要病因,停用了哌醋甲酯治疗。尼莫地平治疗后结果良好。我们还描述了法国药物警戒数据库中记录的另外两例哌醋甲酯诱发的RCVS病例。此外,在国际药物警戒数据库(VigiBase®)中,RCVS是一种比预期更频繁报告的与哌醋甲酯有关的不良反应,提示存在药物警戒信号。鉴于其药效学,即对突触前多巴胺和去甲肾上腺素再摄取的抑制作用,理论上哌醋甲酯可能导致这一血管事件。
在接受治疗的患者中观察到RCVS诊断时,需要考虑哌醋甲酯的作用。尽管这种潜在药物不良反应的发生率预计很低,但鉴于哌醋甲酯的使用不断增加,临床医生应意识到其可能发生。